Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...
Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...
Extends Gratitude to Outgoing Board Members for Their Years of Dedicated Service to the IMF BoardSTUDIO CITY, Calif., Nov. 26 ...
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...
Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...
GlobalData on MSN2d
GSK eyes up combo approval for previously withdrawn myeloma drugThe US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
Twin sisters Linda Thomas and Karen Rodman are back home after a kidney transplant from one twin to the other at Cedars-Sinai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback